Alerta

IMMUNE CELL-DERIVED SECRETOME

Resumen de: US20260243757A1

0000 There is provided a composition comprising a secretome obtained by culturing an immune progenitor cell in the presence of an agent that activates the immune cell progenitor to an activated immune cell. Also provided is a composition for use in tissue regeneration, a method of generating a macrophage-derived secretome, a method of screening a drug and a method of culturing a proliferative cell.

BUTYROPHILIN A2 AND RELATED ISOFORMS FOR THE TREATMENT OF AUTOIMMUNITY AND INFLAMMATION

Resumen de: US20260242441A1

Described herein are methods of reducing CD3-dependent T cell signaling in a subject in need thereof. Also described are method of increasing T-regulatory (Treg) cells, or decreasing T-helper 17 (Th17) cells. These methods involve administering butyrophilin A2 (BTN2A2), a BTN2A2 fragment thereof, a BTN2A2-related isoform, or a BTN2A2-related isoform fragment, or a conjugate or fusion polypeptide comprising any of the foregoing to the subject. These methods are beneficial for patients with autoimmune disorders and inflammatory disorders such as allergy, asthma, glomerulonephritis, inflammatory bowel disease, rheumatoid arthritis, an autoimmune or inflammatory neurological disease, antibody mediated transplant rejection, infantile cholestasis, haemophagocytic lymphohistiocytosis, erythrocytic haemophagocytosis, malnutrition, systemic lupus erythematosus (lupus), psoriasis, myasthenia gravis or HIV. Further described are fusion proteins having BTN2A2 and an Fc domain.

METHOD

Resumen de: US20260243781A1

A method of measuring oxidative stress in a cell or tissue sample, the method including the steps of: (i) treating the cell or tissue sample in a medium; (ii) collecting a portion of the medium; (iii) measuring amounts of glutathione in the cell or tissue sample; and (iv) measuring amounts of reactive oxygen species (ROS) in the media portion collected in step (ii), step (iii) being carried out immediately after steps (i) and (ii), and step (iv) being carried out simultaneously with step (iii) or within 6 hours of step (iii) including assay time if the collected media portion is stored at about 0-8° C. until step (iv) is carried out.

THERAPEUTIC TARGETING OF TUMOR ESCAPE BY CAR-MEDIATED TROGOCYTOSIS

Resumen de: US20260241002A1

Populations of CAR T cells that exhibit reduced trogocytosis are disclosed, as well as methods for making such cells and methods of using such cells in the treatment of cancer. A reduction in trogocytosis is achieved by inhibiting Cathepsin B in the CAR T cells and/or inducing ubiquitylation of cancer antigens taken up by the CAR T cells.

METHODS FOR THE DIAGNOSIS AND TREATMENT OF PRECLINICAL ALZHEIMER'S DISEASE

Resumen de: WO2026173983A1

The present invention provides methods and biomarkers useful for detecting, diagnosing and treating Alzheimer's Disease. The biomarkers for diagnoses may be used to develop treatment plans for subjects. The methods may be used to diagnose a subject prior to clinical onset of symptoms and may allow for early treatment which may slow progression of the disease.

Predicting adverse events from immunotherapy

Resumen de: AU2026210844A1

The disclosure relates to methods of diagnosis and prognosis, compositions for immunotherapies, methods of improving said compositions, and immunotherapies using the same (e.g., T cells, non- T cells, TCR-based therapies, CAR-based therapies, bispecific T-cell engagers (BiTEs), and/or immune checkpoint blockade). ul u l

METHOD FOR CONTROLLING MEMBRANE POTENTIAL-DEPENDENT ION CHANNEL THROUGH TYPE I TASTE RECEPTORS (T1RS)

Resumen de: US20260240820A1

The present invention pertains to a method for controlling a membrane potential-dependent ion channel (VGSC or the like) through a type I taste receptor present in a nerve cell or the like. In the present invention, it has been found that an Aβ peptide, or a sweet amino acid or an umami substance specifically binds to a type I taste receptor on the surface of a nerve cell to exert an agonist-like or antagonist-like action, thereby amplifying or suppressing a VGSC active current.Moreover, with the binding of an Aβ peptide or the like to a type I taste receptor, the amplification of a VGSC active current occurs, the overactivity of nerve cells causing epileptiform attack occurs, and a large number of substances, which can effectively suppress the amplification of the VGSC active current, among ligand substances that specifically bind to the type I taste receptor, can be found.The present invention provides: a type I taste receptor-specific ligand substance that can control the amplification or suppression of a VGSC active current; and a pharmaceutical composition for preventing or treating various neurodegenerative diseases, such as Alzheimer's disease (AD), due to the amplification of a VGSC active current caused by the binding of an Aβ peptide or the like to a type I taste receptor. Moreover, a method for using, as a target receptor, a type I taste receptor present in a nerve cell or the like to screen a ligand substance for controlling a VGSC or the like in the cell is al

GQ/11 Protein Peptidomimetics

Resumen de: US20260242759A1

0000 The present invention relates to G protein peptidomimetics, in particular Gprotein peptidomimetics, capable of stabilizing a GPCR, in particular a Gprotein-coupled receptor, in an active conformational state. The G protein peptidomimetics are derived from the α<5 >helix of Gαprotein or mini-Gprotein, in particular they arise from modifications of peptides comprising or consisting of the amino acid sequence set forth in SEQ ID NO:13 or SEQ ID NO:14. The invention further provides complexes of the G protein peptidomimetics and a GPCR, fusion polypeptides of a GPCR and the G protein peptidomimetics and compositions comprising the same. Further disclosed herein are uses of the G protein peptidomimetics, complexes, fusion polypeptides and compositions for determining the structure of a GPCR conformer, for screening for compounds capable of specifically binding to a GPCR conformer and as allosteric modulator of a GPCR and as a biosensor.

MOLECULAR PROBE FUNCTIONALIZED ELEMENT

Resumen de: US20260243761A1

The present invention provides a molecular probe functionalized element comprising a solid base element, a first layer comprising a linker A, a second layer comprising a peptide compound, a third layer comprising a linker B, and a fourth layer comprising a molecular probe, wherein the peptide compound is covalently bound to the solid base element via linker A and the molecular probe is covalently bound to the peptide compound via linker B. The present invention also provides a process for preparing the molecular probe functionalized element and a device comprising the molecular probe functionalized element such as an optical biosensor. Further, the present invention provides a method for detecting a biomarker comprising a) bringing into contact the molecular probe functionalized element with a sample suspected to comprise a target analyte; b) detecting the biomarker based on an interaction between the molecular probe and the target analyte. The present invention also provides a use of the molecular probe functionalized element or of the device for one or more of: a companion diagnostic test; diagnosing Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Diabetes, Huntington, Prion disease, or a tumor in a patient; monitoring of therapy of patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Diabetes, Huntington, Prion disease, or a tumor; and screening of drugs for the treatment of Alzheimer's disease, Parkinson's disease

NOVEL INHIBITORS OF HISTONE METHYLTRANSFERASE NUCLEAR LOCALISATION

Resumen de: US20260242753A1

The present invention relates to novel therapeutic compositions and methods for treating cancer. In particular, the use of proteinaceous inhibitors, including novel bicyclic peptide inhibitors, for use in treating cancer.

ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF

Resumen de: WO2025076635A1

Described herein are anti-alpha-synuclein antibodies. More specifically, described herein are antibodies specific to serine 129 phosphorylated alpha-synuclein. Further described herein is the use of the anti alpha-synuclein antibodies for the treatment or diagnosis of a synucleinopathy. Further described are kits and compositions comprising the anti alpha-synuclein antibodies detecting alpha-synuclein in a sample.

DETECTION OF DISEASE STATE MACROMOLECULES BINDING TO NORMAL MACROMOLECULES AS A BIOMARKER FOR DISEASE IDENTIFICATION

Resumen de: WO2025080894A1

In one aspect, the present disclosure provides a method of detecting a presence or absence of a biomarker for a disease in the sample, wherein the biomarker comprises: a) a complex of physiologically active target macromolecules or a fragment or portion thereof and target macromolecules that are not physiologically active; b) a conformation of the physiologically active macromolecules or fragment thereof when the physiologically active target macromolecules or the fragment or portion thereof is a complex with a non- physiologically active target macromolecule; c) the conformation of physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; d) the conformation of non-physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; or e) a combination of a), b), c), d) and/or e).

新規な選択的ＡＣＫＲ２モジュレーター

Resumen de: WO2025027065A1

The application discloses selective chimeric chemokines and their use for selectively targeting atypical chemokine receptor 2 (ACKR2) in the treatment of an autoimmune, inflammatory, neurological, cardiovascular or proliferative disease or disorder in a subject and/or for use in improving the response of a subject to anticancer immunotherapy. The application further discloses pharmaceutical compositions comprising such selective chimeric chemokines and further provides methods of production and uses of said chimeric cytokines.

PEPTIDES BLOCKING AMYLOID FIBRIL GROWTH

Resumen de: EP4793283A1

The present invention belongs the field of biomedicine, namely, treating and preventing Parkinson's and Alzheimer's diseases. These diseases are characterized by the presence of amyloid fibrils that drive the pathology progression in the brains of affected individuals. The invention discloses peptides that block ends of amyloid fibrils and stop their growth.

診断方法

Resumen de: WO2021089651A1

The current application relates to personalised nutrition methods, particularly to methods of determining whether a human subject would benefit from taking a urolithin supplement and methods for determining the treatment dose of a urolithin supplement for a human subject. Particularly methods comprising determining the level of urolithin or a urolithin conjugate in a biological fluid, such as a dried whole blood spot sample, a dried plasma spot, a m spot sample or a urine sample The current application also relates to systems for presenting whether a human subject would benefit from taking a urolithin supplement and for presenting the treatment dose of a urolithin supplement for a human subject. The current application also relates to computer implementation of methods of the invention.

用于磷酸化Tau蛋白pTau181检测的抗体、免疫检测方法及应用

Resumen de: CN122587066A

本申请公开了一种用于磷酸化Tau蛋白pTau181检测的抗体、免疫检测方法及应用。本申请抗体包括T181‑1B4抗体；T181‑1B4的轻链CDR1、CDR2和CDR3依序为SEQ ID NO.1至3所示序列，重链CDR1、CDR2和CDR3依序为SEQ ID NO.4至6所示序列。基于本申请抗体对磷酸化Tau蛋白pTau181进行免疫检测，操作简单、灵敏度高、特异性强，可实现磷酸化Tau蛋白pTau181快速检测，对评估Tau蛋白磷酸化水平和Tau蛋白pTau181磷酸化相关检测具有重要意义。

Tau蛋白免疫传感器及其制备方法

Resumen de: CN122591958A

0001 本发明提供了Tau蛋白免疫传感器及其制备方法，其中，Tau蛋白免疫传感器的制备方法包括：使锰掺杂二硫化钼与金源以获得金纳米粒子‑锰掺杂二硫化钼复合体；使含有所述金纳米粒子‑锰掺杂二硫化钼复合体的悬浮液覆盖丝网印刷电极上，以在所述丝网印刷电极的表面形成复合体层；S3：在所述复合体层上覆盖抗Tau蛋白抗体溶液并孵育至少1小时，然后洗去多余抗Tau蛋白抗体溶液，得到抗Tau蛋白抗体层；及S4：封闭抗Tau蛋白抗体层上的非特异性结合位点，得到所述Tau蛋白检测传感器。根据试验确定，本发明构建的Tau蛋白免疫传感器的检测限可以低至20fM。

用于T细胞疗法的诊断方法

Resumen de: PH12017502153A1

The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.

神経変性疾患の診断などを補助する方法、キット、バイオマーカーおよびバイオマーカーセット

Resumen de: JP2026132804A

0001 【課題】神経変性疾患の診断を補助する方法、およびアルツハイマー型認知症とパーキンソン病の鑑別を補助する方法；神経変性疾患の診断キット、およびアルツハイマー型認知症とパーキンソン病の鑑別キット；並びに神経変性疾患の診断用バイオマーカー、神経変性疾患の診断用バイオマーカーセット、およびアルツハイマー型認知症とパーキンソン病の鑑別用バイオマーカーセットを提供すること。 【解決手段】被検試料中の、細胞外小胞におけるＣＤ４１の量またはＣＤ６１の量を検出することを含む神経変性疾患の診断を補助する方法であって、上記ＣＤ４１の量またはＣＤ６１の量を含む指標が、神経変性疾患以外の対象よりも低いことが、神経変性疾患を示唆する、神経変性疾患の診断を補助する方法。 【選択図】なし

一种用于阿尔茨海默病诊断的生物标志物组合及其检测试剂盒

Resumen de: CN122588234A

本发明公开了一种用于阿尔茨海默病诊断的生物标志物组合及其检测试剂盒，涉及生物医学及分子诊断技术领域，所述生物标志物组合包括检测以下基因或其编码蛋白的表达水平的试剂：胶质纤维酸性蛋白基因 GFAP、前蛋白转化酶1基因 PCSK1、可溶性耐药相关钙结合蛋白基因 SRI、SWI/SNF染色质重塑复合物亚基C1基因 SMARCC1、双特异性酪氨酸磷酸化调节激酶2基因 DYRK2 和神经肽Y基因 NPY。本发明的生物标志物组合不仅可在脑组织样本中实现有效检测，还可在外周血、血浆、血清或脑脊液等临床易于获取的样本中稳定检出，为阿尔茨海默病的大规模人群筛查和早期辅助诊断提供了一种无创、简便且易于推广的检测方案。

一种自供电光电化学免疫传感平台及其制备方法和应用

Resumen de: CN122567800A

0001 本发明涉及一种自供电光电化学免疫传感平台及其制备方法和应用，属于光电化学生物传感器技术领域。所述传感平台包括光电阴极和光电阳极，所述光电阴极包括第一FTO导电基底和位于所述导电基底表面的NU66/T‑D‑COF复合光阴极材料，所述NU66/T‑D‑COF复合光阴极材料表面依次固定有Aβ捕获抗体和牛血清白蛋白封闭层；所述光电阳极包括第二FTO导电基底和位于所述导电基底表面的NCS@ZIS复合光阳极材料。本发明提供的传感平台能够解决传统自供电平台检测淀粉β样蛋白过程中存在的基质干扰强、光电转换效率低、信号放大能力有限的技术问题，为AD早期诊断提供高灵敏、抗干扰的自供电检测新策略。

一种阿尔茨海默症标志物P-tau181的单分子检测方法

Resumen de: CN122568008A

0001 本发明提供一种阿尔茨海默症标志物P‑tau181的单分子检测方法，属于生物技术领域。该方法包括：制备由捕获抗体包被的酶标板；制备由检测抗体包被的荧光颗粒；利用酶标板捕获目标蛋白P‑tau181；利用荧光颗粒进行荧光信号放大；利用显微荧光成像系统进行数字化成像与分析。本发明采用50‑300nm荧光颗粒实现高效信号放大，结合免液路显微成像系统进行单分子计数，检测限低至150fg/mL，R<2>=0.9996。本发明具有灵敏度高、仪器成本低、中高通量、操作简便、可视性好等优点，适用于阿尔茨海默症的大规模早期筛查、预警、临床辅助诊断及长期监测。

抗磷酸化Tau217的单克隆抗体及其试剂盒

Resumen de: CN122562946A

0001 本申请涉及一种特异性识别磷酸化 Tau217 蛋白的单克隆抗体、其制备方法，以及包含该抗体的磷酸化 Tau217 蛋白检测试剂盒，该抗体可用于阿尔茨海默病的早期辅助诊断、病程监测及疗效评估。本发明试剂盒空白限为 0.51 pg/mL，检出限为 1.04 pg/mL，定量限为 3.93 pg/mL，线性范围 0.5‑100 pg/mL（线性相关系数 r≥0.99），批内精密度 CV≤8%，批间精密度 CV≤15%，抗干扰性良好，试剂盒稳定性为 12 个月，开瓶后机载稳定期 30 天，与进口参比试剂盒相关性良好。

检测P-选择素的试剂在制备辅助诊断青光眼的产品中的应用

Resumen de: CN122568014A

0001 本发明公开了检测P‑选择素的试剂在制备辅助诊断青光眼的产品中的应用，涉及青光眼辅助诊断技术领域。与健康对照组相比，青光眼患者血浆中P‑选择素水平显著升高，且在原发性开角型青光眼和原发性闭角型青光眼患者中同样表现出P‑选择素水平显著升高。不同疾病严重程度的患者血浆中的P‑选择素水平与健康对照组相比表现出P‑选择素水平显著升高。P‑选择素浓度对区分健康对照者与青光眼患者具有良好的鉴别效能，本发明为青光眼的辅助诊断提供了一种新的选择。

基于SERPINA5的PASC相关心血管系统症状风险评估应用

Nº publicación: CN122564109A 14/08/2026

Solicitante:

中日友好医院（中日友好临床医学研究所）

Resumen de: CN122564109A

0001 本发明涉及生物医药技术领域，尤其是涉及基于SERPINA5的PASC相关心血管系统症状风险评估应用。本发明提供了一种以SERPINA5为核心分子标志物的风险评估体系，该体系能够在常规检测手段难以提供充分解释的情况下，为PASC相关心血管系统症状风险评估提供客观、可量化的分子层面参考依据。